chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient developed initial rash / hives on torso and legs around 22 hours after vaccination. Rash got progressively worse over the course of Sunday Aug 7th, turning into a broad red rash covering about half of his torso and legs. Treated with 2 doses of benadryl over the course of the afternoon / evening on the advice of a telehealth call with a nurse from Pediatric   We took Patient to the same pediatrician office on Monday Morning (Aug 8th) and he was seen around 8am. Diagnosed as a likely allergic reaction to the amoxicillin he was taking at the time.  Pediatrician / CPNP prescribed steroids, once per day, for 3 days starting Aug 8th.   As of today Aug 9th, after two days of taking the steroid (and benadryl), rash has improved slightly but still present over much of the torso and legs. Only other signs/symptoms are slightly increased irritability and disrupted sleep.
No adverse event reported by patient, expired vaccine was administered. Was transferred from Freezer to frifge on 4/1 however vial expired according to manufacturer expiration on 4/1/2022
Psoriasis on both legs below the knees. Never had this before in my life. Will not go away seems to be getting worse. Have not seen a doctor yet.
5-9-13 C/O tenderness and warmth, ice and MOTRIN used. 5-10-13 3.5 inch circle of non-swollen redness, non-tender, slightly pruritic on (R) deltoid, 4.0 inch area on (L) (deltoid) arm, non-tender, slightly pruritic, Localized reaction bilaterally.
Nausea; This spontaneous case was reported by a consumer and describes the occurrence of NAUSEA (Nausea) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 026L20A and 028L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 30-Dec-2020, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Jan-2021, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 30-Dec-2020, the patient experienced NAUSEA (Nausea). On 31-Dec-2020, NAUSEA (Nausea) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.  Treatment information was not provided.  Action taken with mRNA-1273 (Moderna COVID-19 Vaccine) in response to the event was not applicable
VERY ITCHY, SWEATING.  ZYRTEC 10MG PO @2PM.    2:10PM SLIGHT LESS ITCHING AND SWEATING.  NO ER REQUIRED.  CLIENT REFUSED
Arm was sore; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (Arm was sore) in a 33-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Down's syndrome.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced MYALGIA (Arm was sore). At the time of the report, MYALGIA (Arm was sore) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Relevant concomitant medications included Thyroid medication for hypothyroidism.  Treatment information included ice.
Patient states there was pain in shoulder, tingling in the hands, and nerve damage. Patient states that the flu vaccination was really painful, but did not identify if it was the injection and/or injection site.
Patient stated a red, itchy rash developed on her arm from around elbow area to shoulder area that she received the vaccine in 2 weeks after her first dose of Moderna. She sought medical attention and was told it was a T-cell reaction to the vaccine.
Wrong vaccine administered; COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  A 64-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 28Sep2022 as dose 5 (booster), single (Lot number: Fe3592), in left arm for covid-19 immunization; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient didn't receive BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5). The patient's relevant medical history included: "Hypothothyroid" (unspecified if ongoing). Concomitant medication(s) included: LEVOTHYROXINE. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 2022, outcome "not recovered" and all described as "COVID 19 Treatment"; WRONG PRODUCT ADMINISTERED (non-serious) with onset 28Sep2022, outcome "unknown", described as "Wrong vaccine administered". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (2022) Positive, notes: COVID 19 Treatment. Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical course: The patient received Paxlovid as COVID 19 Treatment, Treatment start date was 13Nov2022, Treatment stop date was 17Nov2022. The patient had no Known allergies.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.; Sender's Comments: Based on the information in the case report and a plausible temporal relationship, a possible causal relationship between the events drug ineffective, covid-19, wrong product administered and suspect drug BNT162B2, BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5). cannot be excluded.
HCP stated no AEs were reported by patients after the vaccines were administered; Patient was administered the Moderna Covid 19 vaccine after use by date; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient was administered the Moderna Covid 19 vaccine after use by date) and NO ADVERSE EVENT (HCP stated no AEs were reported by patients after the vaccines were administered) in an adult patient of an unknown gender who received mRNA-1273 (Spikevax) (batch no. 013B22A) for COVID-19 vaccination.     No Medical History information was reported.   On 31-Aug-2022, the patient received second dose of mRNA-1273 (Spikevax) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 31-Aug-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient was administered the Moderna Covid 19 vaccine after use by date). On an unknown date, the patient experienced NO ADVERSE EVENT (HCP stated no AEs were reported by patients after the vaccines were administered). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Patient was administered the Moderna Covid 19 vaccine after use by date) and NO ADVERSE EVENT (HCP stated no AEs were reported by patients after the vaccines were administered) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (HCP stated no AEs were reported by patients after the vaccines were administered) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Patient was administered the Moderna Covid 19 vaccine after use by date).    No concomitant medication was reported.  beyond use date (BUD) reported as 28-Aug-2022.  It was unknown whether the vial was initially stored in the refrigerator. It was unknown whether the vial underwent any temperature excursions.  No treatment medication was reported.   Most recent FOLLOW-UP information incorporated above includes: On 07-Sep-2022: Live follow up received no new information.
No adverse event; Pharmacist called to report AE for PNEUMOVAX23. Caller stated she received "third hand" information that a 75-year-old female was administered a dose of PNEUMOVAX23 after it's expiration date at a Health Care Provider's office. Caller stated date o; This spontaneous report was received from a pharmacist refers to a 75-year-old female patient.  The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On 03-OCT-2023, the patient was vaccinated with one dose of pneumococcal vaccine, polyvalent (23-valent)(PNEUMOVAX23) (lot #, expiration date, exact dose, route of administration and anatomical location were not reported) for prophylaxis.   The caller stated she received ''third hand'' information that a 75-year-old female was administered a dose of pneumococcal vaccine, polyvalent (23-valent)(PNEUMOVAX23) after its expiration date at a Health Care Provider's office (expired product administered). The patient was asymptomatic. No additional adverse event reported (no adverse event).
No adverse event; on unspecified date an unspecified number of patients were administered improperly stored PEDVAXHIB, ROTATEQ, and VAQTA; This spontaneous report was received from a medical assistant referring to a 4-months-old female patient. The patient's medical history, concurrent condition and concomitant medication were unknown.  On 25-OCT-2019, the patient was vaccinated with improperly stored rotavirus vaccine, live, oral, pentavalent (ROTATEQ) vial of lot# S005878, expiration date reported as 26-NOV-2020, but upon internal validation established as 25-NOV-2020 (strength, dose, dose number and route of administration were unknown) for prophylaxis (product storage error).   On an unknown date, the vaccine was stored at a temperature above 47 degrees Fahrenheit/9 degrees Celsius (9.3 Celsius (C)) for 23 minutes. Previous temperature excursion was at a temperature above 47 degrees Fahrenheit/9 degrees Celsius (10.7 C) for 33 minutes, 47 degrees Fahrenheit/9 degrees Celsius (8.7 C) for 36 minutes, 47 degrees Fahrenheit/9 degrees Celsius (8.9 C) for 15 minutes and 47 degrees Fahrenheit/9 degrees Celsius (9 C) for 12 minutes. Digital data logger was involved. No adverse event was reported.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-1910USA012749:
developed a rash about a week after the shot on the left side that turned out to be shingles
Patient fainted. When I arrived patient was awake. He drank some orange juice and relaxed for about 30 minutes. Patient felt better and went home.
epididymaorchitis 9 days p/vax-ultrasound, ATB & observations
This spontaneous case reported by a consumer, describes the occurrence of vaccination complication (have to get a doctor) in a male patient, of an unknown age, who received mRNA-1273 (Moderna COVID-19 vaccine) for COVID-19 immunization. No medical history reported. On an unknown date, patient received a dose of mRNA-1273 (Moderna COVID-19 vaccine), unknown route; 1 dosage form. On an unknown date, patient experienced vaccination complication (have to get a doctor). At the time of the report, vaccination complication (have to get a doctor) outcome: unknown. The action taken with mRNA-1273 (Moderna COVID-19 vaccine): unknown. No concomitant medication or treatment information reported.
Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) in a 49-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 044B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 15-Apr-2021 at 3:30 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 15-Apr-2021 at 3:30 PM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The age of patient was provided as 49.96 years.  Concomitant and Treatment medications were not reported.  On 06-Apr-2021, the vaccine with batch number 044B21A  was moved to fridge. On 15-Apr-2021, 3 vials were moved to the clinic. On 15-Apr-2021 at 9 AM , vials underwent temperature excursion with temperature of 34 degrees Fahrenheit. . On 15-Apr-2021 18 vials were moved to the clinic. The condition of vaccine prior to vaccination was not frozen. The vaccine beyond use date was reported as 9-May-2021.  It was reported that, the storage condition at the time of the excursion was cooler storage during high-pace COVID-19 vaccination clinic.  The vials were only punctured right before administration and all doses were drawn from the vial due to high-pace clinic.  Temperature recordings were taken using a Fisherbrand traceable temperature monitor at every hour. It was reported that, the patient was administered with vaccine that experienced more than 1 temperature excursion during 33 weeks on 2021. The health care professional explained that each time a vial was put into a cooler, there was a period of 1 hour or 1 hour and a half approximately, when the temperature data logger registered 34 or 35 degree Fahrenheit.   This case was linked to MOD-2022-566976 (Patient Link).
I started having trouble with my vision. I wasn't seeing things in my right eye very well at far distances. I went to the eye doctor, and they told me I didn't have Glaucoma. I had Cataract surgery a while ago and he thinks I am having issues with my Cataract lens. I had to go to a Neurologist because I am also having Vertigo. The last time I had it was 27 years ago, but it came about 7 or 8 years ago. I have an appointment with a specialist soon, but in the meantime, I am taking Meclizine.
On the 7th around 2pm I noticed the injection site felt warm.  On the 8th it began to itch and was tender to the touch, was reddening,  and began to feel thick under skin (swelling a bit).  On the 9th the itching is constant, the reddened area is just over 2 inches in diameter, warm to the touch, and slightly swelled.  Treatment is consisting of cool compresses and anti-itch cream. Will contact my GP if it worsens. I will still get my second dose on 03/25/2021.
LOCALIZED ITCHING AT SITE OF INJECTION WHICH SPREAD TO ITCHING OF BOTH ARMS, NECK, FACE, AND EARS.
Cough; Body ache; Chills; Fever; Headache; This spontaneous case was reported by a consumer and describes the occurrence of COUGH (Cough), PAIN (Body ache), CHILLS (Chills), PYREXIA (Fever) and HEADACHE (Headache) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form.   On 04-Feb-2021, the patient experienced COUGH (Cough), PAIN (Body ache), CHILLS (Chills), PYREXIA (Fever) and HEADACHE (Headache). At the time of the report, COUGH (Cough), PAIN (Body ache), CHILLS (Chills), PYREXIA (Fever) and HEADACHE (Headache) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 04-Feb-2021, Body temperature: 101.7 (High) 101.7 and 102.7 (High) 102.7 by midnight.  The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   Concomitant product use was not provided by the reporter. No treatment information was provided.
Acute Transverse Myelitis Dx in hospital requiring a hospital stay spanning nearly 2 weeks.
screaming for 5hr p/vax w/some nocturnal myoclonic jerking, no fever;next day no problems, back to nl;
RECEIVED EXPIRED VACCINE; This spontaneous report received from a physician concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported.  The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 05-JUN-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported.  On 05-JUN-2021, the subject experienced received expired vaccine. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of received expired vaccine was not reported. This report was non-serious.
syncope; Dizziness; vertigo; This is a spontaneous report from a contactable consumer (patient). A patient of unspecified age and gender received both 1st and 2nd doses of BNT162B2, via an unspecified route of administration on an unspecified date at single dose for covid-19 immunisation. The patient's medical history and concomitant medications were not reported. It was reported that the patient had received two of the COVID vaccine and would like to report about a possible side effect. Three days after each shot the patient had an episode of dizziness with vertigo and syncope. The patient was not sure if this was related to the vaccine but since the patient had not had this before and wanted to report.  Information on the Lot/batch number has been requested.
17 year old who received the first dose of Moderna COVID-19 Vaccine; This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (17 year old who received the first dose of Moderna COVID-19 Vaccine) in a 17-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 021B21A) for COVID-19 vaccination.     No medical history were reported. .     On 02-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Jul-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (17 year old who received the first dose of Moderna COVID-19 Vaccine). On 02-Jul-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (17 year old who received the first dose of Moderna COVID-19 Vaccine) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication was reported. No treatment medication were provided. No lab data has been provided by the reporter.
I had the chills and fever. I felt like I could not get warm for 2 or 3 days. I have started having body aches. At the site of the injection was red and slight swollen. It was hot to the touch. I had nausea and dizziness off and on. I had nasal congestion. A couple weeks I was dx with strep throat. I have got bitter but with the nasal congestion is still happening.
?Covid arm? - delayed reaction on my arm at injection site. Skin is red, swollen, hot to touch and  itchy.
they had an allergic reaction; This spontaneous case was reported by a non-health professional and describes the occurrence of HYPERSENSITIVITY (they had an allergic reaction) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced HYPERSENSITIVITY (they had an allergic reaction). At the time of the report, HYPERSENSITIVITY (they had an allergic reaction) outcome was unknown.            No concomitant medications were reported. No treatment medications were reported.
profuse diaphoretic;violent vomiting;color pale, lightheaded & dizzy;seen in ER 230PM given DPH & discharged 410PM;
Local shot reaction on (L) arm with itching on face BENADRYL QHS it if worsen did discuss ER or Steroid INJ.
Headache for 4 days, neck ache for 5 days, chills for 2 hours the same day of administration, arm ache for 4 days, fatigue for 2 days
head and body aches and fatigue April 6 treated with ibuprophen and rest, body started itching April 7 treated with Aveeno lotion, broke out in hives all over torso and legs Arpil 8 treated with oatmeal bath , rest and meditation.  Hives gone by April 10.
This spontaneous report as received from a pharmacist refers to a 53 years old female patient without drug reactions or allergies. The patient's medical history included herpes simplex, genital herpes and shingles. On 07-JAN-2013, the patient was vaccinated subcutaneously in the left arm with a dose of 0.65 ml live ZOSTAVAX (lot number H018088, expiration date: unspecified). No other co-suspects were reported. No concomitant medications were reported. Past drug therapy included: VALTREX. The pharmacist reported that on 08-JAN-2013, the patient developed tenderness and swelling of her left arm at the injection site and around to the back on her arm and up into her left underarm area, after received live ZOSTAVAX. The patient also developed shingle like lesions on her left arm. It was reported that the patient's arm was getting worse each day. The pharmacist stated that the patient had shingles on the same side she had a few years ago, on her left trunk. Pharmacist stated that there was also lymph node involvement, there was a lump in patient's left underarm. The patient had tenderness and swelling, at the injection site of left arm that was silver dollar in size. Tenderness and swelling also extended from left elbow to the top of left arm. The patient seems to have blotches, not pustules on her left arm. The patient did not feel like she had a temperature. The patient sought medical attention by phone call to pharmacy. The patient would follow-up with her health provider. No treatment information was reported. At the time of the report, the patient had not recovered from the adverse events. The relatedness for the adverse events was unknown for live ZOSTAVAX. Additional information has been requested.
Patient states that she had extreme redness, swelling  and pain at the injection site.  She states that she has had the flu shot numerous times and has never had this reaction before.
Post vax, had SOB and headache and ringing in ear, immediately. Had a spot on leg sore from previous years prior, soreness in joint, sharp pain in wrist, nausea and vomiting, At 22:00, temperature 102F (orally) 6 hours after, had hives on inside of legs and at 24 hours after, was weak but normal.
Narrative: COVID infection following COVID vaccine series 02/17, Pfizer, dose #1 03/10, Pfizer, dose #2 08/31 pt cc: cough, fever, headache, loss of taste or smell, Rhinorrhea exposure: unknown 09/08 COVID swab, result: detected 09/08 SARS-COV-2 Variant Sequencing result: pending
Chills diaphoresis  nausea  vomiting headache weakness  Seen in the local ER with fluids toradol and Zoltan Diaphoresis continued for a Another 12 hours
Mother states one week after Pt received Comvax started with fever that went up to 104.9.  Went to ER.  Fever x3 days.  Site red & tender Rt thigh.